Japan approves AstraZeneca’s Ultomiris for generalised myasthenia gravis
Ultomiris is a long-acting C5 complement inhibitor that provides immediate, complete and sustained complement inhibition. It is indicated for adult gMG patients, who are anti-acetylcholine receptor (AChR) antibody-positive,